Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00992862 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of Moexipril HCl 15 mg Tablets Under Fasting Conditions
A Phase 1 study, sponsored by Paddock Laboratories.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00992862: Completed Phase 1 study, sponsored by Paddock Laboratories.
NCT00992862 is a Phase 1 study that has completed, run by Paddock Laboratories. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00992862, a Phase 1 study, has completed, sponsored by Paddock Laboratories.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the relative bioavailability of Moexipril HCl 15mg tablets (by Paddock Laboratories, Inc.) with that of Univasc® 15mg tablets (by Schwarz Pharma) following a single oral dose (1 x 15mg tablet) in healthy, adult subjects under fasting conditions.
Interventions
- DRUG Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc.
- DRUG Univasc® 15mg Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00992862
The ClinicalTrials.gov registry entry for NCT00992862 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Paddock Laboratories, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc. is the first listed.
NCT00992862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00992862 about?
NCT00992862 is a clinical study titled "A Relative Bioavailability Study of Moexipril HCl 15 mg Tablets Under Fasting Conditions". The purpose of this study is to compare the relative bioavailability of Moexipril HCl 15mg tablets (by Paddock Laboratories, Inc.) with that of Univasc® 15mg tablets (by Schwarz Pharma) following a single oral dose (1 x 15mg tablet) in healthy, adult subjects under fasting conditions.
What is the current status of trial NCT00992862?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants.
What interventions are being tested in trial NCT00992862?
The interventions under investigation include: Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc. (DRUG), Univasc® 15mg Tablets (DRUG).
Who is sponsoring clinical trial NCT00992862?
This trial is sponsored by Paddock Laboratories, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.